Zankiren

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571190

CAS#: 138742-43-5

Description: Zankiren is a renin inhibitor. It can reduce blood pressure, plasma renin activity, and angiotension II. It can decrease blood pressure and circulating components of the RAS in normotensive volunteers as a result of documented absorption.


Price and Availability

Size
Price

Size
Price

Size
Price

Zankiren is not in stock, may be available through custom synthesis. For cost- effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 571190
Name: Zankiren
CAS#: 138742-43-5
Chemical Formula: C35H55N5O6S2
Exact Mass: 705.3594
Molecular Weight: 705.97
Elemental Analysis: C, 59.55; H, 7.85; N, 9.92; O, 13.60; S, 9.08


Synonym: Zankiren; A 72617; A-72517; A72517

IUPAC/Chemical Name: 4-Thiazolepropanamide, N-((1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2S)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (alphaS)-

InChi Key: YFDSDRDMDDGDFC-HOQQKOLYSA-N

InChi Code: InChI=1S/C35H55N5O6S2/c1-25(2)18-32(41)33(42)30(20-27-12-8-5-9-13-27)37-35(44)31(21-29-22-47-24-36-29)38-34(43)28(19-26-10-6-4-7-11-26)23-48(45,46)40-16-14-39(3)15-17-40/h4,6-7,10-11,22,24-25,27-28,30-33,41-42H,5,8-9,12-21,23H2,1-3H3,(H,37,44)(H,38,43)/t28-,30+,31+,32+,33-/m1/s1

SMILES Code: O=C(N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)CC(C)C)[C@@H](NC([C@@H](CS(=O)(N2CCN(C)CC2)=O)CC3=CC=CC=C3)=O)CC4=CSC=N4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Ménard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation. 1995 Jan 15;91(2):330-8. PubMed PMID: 7805235.

2: Jadhav M, Yeola C, Zope G, Nabar A. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. J Postgrad Med. 2012 Jan-Mar;58(1):32-8. doi: 10.4103/0022-3859.93250. Review. PubMed PMID: 22387646.

3: Tzoupis H, Leonis G, Avramopoulos A, Reis H, Czyżnikowska Ż, Zerva S, Vergadou N, Peristeras LD, Papavasileiou KD, Alexis MN, Mavromoustakos T, Papadopoulos MG. Elucidation of the binding mechanism of renin using a wide array of computational techniques and biological assays. J Mol Graph Model. 2015 Nov;62:138-49. doi: 10.1016/j.jmgm.2015.09.015. Epub 2015 Sep 25. PubMed PMID: 26421414.

4: Fisher ND, Hollenberg N. Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther. 1995 Mar;57(3):342-8. PubMed PMID: 7697952.

5: Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005 Feb;23(2):417-26. PubMed PMID: 15662231.

6: Rosenberg SH, Spina KP, Condon SL, Polakowski J, Yao Z, Kovar P, Stein HH, Cohen J, Barlow JL, Klinghofer V, et al. Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517). J Med Chem. 1993 Feb 19;36(4):460-7. PubMed PMID: 8474102.

7: Gupta SL, Patel JP, Jones DL, Partipilo RW. Parenteral formulation development of renin inhibitor Abbott-72517. J Pharm Sci Technol. 1994 Mar-Apr;48(2):86-91. PubMed PMID: 8032800.

8: Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005 Mar;16(3):592-9. Epub 2005 Feb 9. Review. PubMed PMID: 15703270.

9: Kleinert HD, Rosenberg SH, Baker WR, Stein HH, Klinghofer V, Barlow J, Spina K, Polakowski J, Kovar P, Cohen J, et al. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science. 1992 Sep 25;257(5078):1940-3. PubMed PMID: 1411510.

10: Frishman WH, Fozailoff A, Lin C, Dike C. Renin inhibition: a new approach to cardiovascular therapy. J Clin Pharmacol. 1994 Sep;34(9):873-80. Review. PubMed PMID: 7983230.

11: Sepehrdad R, Frishman WH, Stier CT Jr, Sica DA. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol Rev. 2007 Sep-Oct;15(5):242-56. Review. PubMed PMID: 17700383.

12: Panzenbeck MJ, Loughnan CL, Madwed JB, Winquist RJ, Fogal SE. Captopril-induced hypotension is inhibited by the bradykinin blocker HOE-140 in Na(+)-depleted marmosets. Am J Physiol. 1995 Oct;269(4 Pt 2):H1221-8. PubMed PMID: 7485552.

13: Wessale JL, Kleinert HD, Calzadilla SV, Kovar PJ, Rosenberg SH. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs. Am J Hypertens. 1993 Jun;6(6 Pt 1):514-21. PubMed PMID: 8343235.